Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATHE NASDAQ:HOOK NASDAQ:LTRN NASDAQ:TPST On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATHEAlterity Therapeutics$5.07$4.91$1.00▼$7.00$44.97M0.413,533 shsN/AHOOKHOOKIPA Pharma$0.95+1.2%$0.99$0.72▼$5.30$11.57M0.97119,235 shs34,005 shsLTRNLantern Pharma$4.31+2.6%$4.14$2.55▼$6.12$45.36M1.4786,966 shs60,678 shsTPSTTempest Therapeutics$10.99+9.6%$8.19$5.33▼$20.67$48.80M-1.9382,298 shs89,139 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATHEAlterity Therapeutics+7.07%+2.63%-1.55%+7.19%+264.75%HOOKHOOKIPA Pharma+1.23%+4.34%+5.17%-39.13%-81.35%LTRNLantern Pharma+2.62%+5.64%-16.15%+29.82%+19.39%TPSTTempest Therapeutics+9.57%+10.79%+55.45%+33.21%-28.96%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATHEAlterity Therapeutics$5.07$4.91$1.00▼$7.00$44.97M0.413,533 shsN/AHOOKHOOKIPA Pharma$0.95+1.2%$0.99$0.72▼$5.30$11.57M0.97119,235 shs34,005 shsLTRNLantern Pharma$4.31+2.6%$4.14$2.55▼$6.12$45.36M1.4786,966 shs60,678 shsTPSTTempest Therapeutics$10.99+9.6%$8.19$5.33▼$20.67$48.80M-1.9382,298 shs89,139 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATHEAlterity Therapeutics+7.07%+2.63%-1.55%+7.19%+264.75%HOOKHOOKIPA Pharma+1.23%+4.34%+5.17%-39.13%-81.35%LTRNLantern Pharma+2.62%+5.64%-16.15%+29.82%+19.39%TPSTTempest Therapeutics+9.57%+10.79%+55.45%+33.21%-28.96%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATHEAlterity Therapeutics 2.50Moderate Buy$12.00136.69% UpsideHOOKHOOKIPA Pharma 2.33Hold$4.50373.93% UpsideLTRNLantern Pharma 3.00Buy$25.00480.05% UpsideTPSTTempest Therapeutics 2.50Moderate Buy$30.00172.98% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATHEAlterity TherapeuticsN/AN/AN/AN/A$1.04 per shareN/AHOOKHOOKIPA Pharma$9.35M1.24N/AN/A$4.25 per share0.22LTRNLantern PharmaN/AN/AN/AN/A$1.96 per shareN/ATPSTTempest TherapeuticsN/AN/AN/AN/A$5.66 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATHEAlterity Therapeutics-$12.54MN/A0.00∞N/AN/AN/AN/AN/AHOOKHOOKIPA Pharma-$43.50M-$5.85N/AN/AN/A-785.66%-120.09%-77.14%11/12/2025 (Estimated)LTRNLantern Pharma-$20.78M-$1.78N/AN/AN/AN/A-99.89%-81.58%11/6/2025 (Estimated)TPSTTempest Therapeutics-$41.84M-$14.59N/AN/AN/AN/A-334.76%-130.63%11/11/2025 (Estimated)Latest HOOK, LTRN, TPST, and ATHE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025LTRNLantern Pharma-$0.53-$0.40+$0.13-$0.40N/AN/A8/11/2025Q2 2025TPSTTempest Therapeutics-$3.23-$2.07+$1.16-$2.07N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATHEAlterity TherapeuticsN/AN/AN/AN/AN/AHOOKHOOKIPA PharmaN/AN/AN/AN/AN/ALTRNLantern PharmaN/AN/AN/AN/AN/ATPSTTempest TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATHEAlterity TherapeuticsN/A12.98N/AHOOKHOOKIPA PharmaN/A3.613.61LTRNLantern PharmaN/A3.523.52TPSTTempest TherapeuticsN/A2.122.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATHEAlterity Therapeutics2.14%HOOKHOOKIPA Pharma63.88%LTRNLantern Pharma28.62%TPSTTempest Therapeutics22.52%Insider OwnershipCompanyInsider OwnershipATHEAlterity Therapeutics38.80%HOOKHOOKIPA Pharma3.30%LTRNLantern Pharma8.50%TPSTTempest Therapeutics4.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATHEAlterity Therapeutics108.87 million5.43 millionNot OptionableHOOKHOOKIPA Pharma16012.19 million11.79 millionOptionableLTRNLantern Pharma2010.80 million9.88 millionOptionableTPSTTempest Therapeutics204.44 million4.23 millionOptionableHOOK, LTRN, TPST, and ATHE HeadlinesRecent News About These CompaniesTempest Therapeutics (NASDAQ:TPST) Shares Down 8.5% - What's Next?August 29, 2025 | americanbankingnews.comTempest Therapeutics: Tempest Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 12, 2025 | finanznachrichten.deTempest Therapeutics Advances Clinical Development with Orphan Drug Designations and Pivotal Trial Clearance for Amezalpat and TPST-1495August 11, 2025 | quiverquant.comQTempest Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 11, 2025 | globenewswire.comMorpheus-Liver Study: A New Horizon in Advanced Liver Cancer TreatmentAugust 4, 2025 | tipranks.comTempest Therapeutics’ Promising Advances in Liver Cancer TreatmentJuly 3, 2025 | tipranks.comTempest Therapeutics Receives NMPA Approval for Pivotal Trial of Amezalpat in Hepatocellular Carcinoma Treatment in China - NasdaqJuly 2, 2025 | nasdaq.comTempest Therapeutics Receives NMPA Approval for Pivotal Trial of Amezalpat in Hepatocellular Carcinoma Treatment in ChinaJune 30, 2025 | quiverquant.comQTempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in ChinaJune 30, 2025 | globenewswire.comTPST - Tempest Therapeutics Inc Valuation - MorningstarJune 27, 2025 | morningstar.comMTPST Tempest Therapeutics, Inc. - Seeking AlphaJune 27, 2025 | seekingalpha.comTempest announces $4.6 million registered direct offering of common stock; shares decline over 13%June 11, 2025 | msn.comTempest Therapeutics, Inc. Announces $4.6 Million Registered Direct Offering of Common StockJune 11, 2025 | quiverquant.comQTempest Announces $4.6 Million Registered Direct Offering of Common StockJune 11, 2025 | globenewswire.comTempest Therapeutics Executives Sign Consulting Agreements, Company Explores Strategic AlternativesJune 7, 2025 | marketwatch.comTempest Therapeutics Shares Up, Executive Team Enters Into Consulting AgreementsJune 7, 2025 | marketwatch.comTPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer TherapyJune 6, 2025 | zacks.comTempest Therapeutics stock rises on EMA Orphan Drug DesignationJune 5, 2025 | au.investing.comTempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCCJune 5, 2025 | globenewswire.comTempest Therapeutics: Tempest Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 16, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHOOK, LTRN, TPST, and ATHE Company DescriptionsAlterity Therapeutics NASDAQ:ATHE$5.07 0.00 (0.00%) As of 09/5/2025Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.HOOKIPA Pharma NASDAQ:HOOK$0.95 +0.01 (+1.23%) As of 09/5/2025 03:49 PM EasternHOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.Lantern Pharma NASDAQ:LTRN$4.31 +0.11 (+2.62%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$4.12 -0.19 (-4.52%) As of 09/5/2025 05:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.Tempest Therapeutics NASDAQ:TPST$10.99 +0.96 (+9.57%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$11.04 +0.04 (+0.41%) As of 09/5/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
